Received Mar 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | U8267AA | OT |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | 2091232 | OT |
Confirmed no symptomatic adverse events. No additional AE; TE for ROTATEQ and VAXELIS. they were administered to one patient following the excursion on 27-FEB-2026; This spontaneous report was received from other health professional and referred to a 7 months female patient. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies, and concomitant therapies were not reported. On an unknown date, Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) (Lot Number: 2091232) (Expiration date: 17-Apr-2026) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine (VAXELIS) (Batch/Lot Number: U8267AA) (Expiration date: 31-Aug-2027) underwent a temperature excursion of 8.6 degree Celsius during 8 minutes; afterwards on 27-Feb-2026, the patient was vaccinated with these improperly stored vaccines (dose, frequency, route of administration, dose number in series were not reported) as prophylaxis (Product storage error). No previous temperature excursions. It was confirmed no symptomatic adverse events, no additional adverse event (No adverse event).